RxDoctor Payments Data

John Tew, MD

Ophthalmology · Hemet, CANPI 1174593354

Payments from drug & device makers

$8,312in general payments, 2019–2025

Across 167 payments — averaging $49.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$5K
  • Alcon$957
  • AbbVie$448
  • Ivantis, Inc$395
  • Bausch & Lomb Americas Inc.$357
  • Novartis$217
  • plus $755 from 15 others

What the payments were for

  • Food & beverage$3,274100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,312 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$420,856
Medicare patients
1,169
Services billed
3,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast97$146,318
RestasisCyclosporine94$122,859
LumiganBimatoprost119$61,032
Cyclosporine86$55,206
RocklatanNetarsudil Mesylat/Latanoprost20$18,148
Difluprednate122$11,035
RhopressaNetarsudil Mesylate20$10,660
Prednisolone Acetate323$9,805
Travoprost47$8,373
MoxifloxacinMoxifloxacin Hcl351$8,138
Latanoprost490$6,541
SimbrinzaBrinzolamide/Brimonidine Tart20$6,356
Tobramycin-DexamethasoneTobramycin/Dexamethasone82$5,039
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$4,647
Brimonidine Tartrate83$4,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$448$183,891213 claims
Bausch & Lomb Americas Inc.Xiidra$357$146,31897 claims
AlconSimbrinza$957$6,35620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →